Quantcast

Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia

December 6, 2010

-Bayer Animal Health enters exclusive supply agreement for Bioniche
reproductive products-

BELLEVILLE, ON, Dec. 6 /PRNewswire/ – Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
today announced that its Australian distributor, Bayer Animal Health, a
division of Bayer Australia Limited, has entered into an exclusive
supply agreement with Angus Australia. Under the agreement, Bayer will
supply Bioniche cattle reproductive products on an exclusive basis to
the breed society for a three-year period. The Angus Association has a
goal of facilitating the production of world-leading Angus genetics and
branded beef.

Bioniche signed a distribution agreement with Bayer Animal Health for
the distribution of two Bioniche cattle reproduction products in June
of this year. Under the agreement, Bayer Animal Health became the
exclusive distributor of Bioniche’s Cue-Mate(TM) and Pregnecol(TM)(   )products in Australia. Cue-Mate(TM) and Pregnecol(TM)( )are high quality products with a proven track record in delivering
consistent results and enhancing reproductive performance in both beef
and dairy cattle. These are the products that will be supplied to AngusAustralia.

More than 1,300 cows have now been artificially inseminated using the
Bioniche products through the “Angus Sire Benchmarking Project” run by
Angus Australia. Bob Dent, Project Co-ordinator, said, “We expect to
shortly reach our target of 2,000 cattle programmed and inseminated
using a one-cycle artificial insemination (AI) program in commercial
herds. This is the largest sire progeny test programme ever launched in
Australia and the members who have nominated bulls will gain great
benefits from their involvement. Bioniche and Bayer have provided
technical advice and personnel to ensure that we receive maximum
benefit from the work that we have put into the AI activities.”

“The agreement with Angus Australia is an indicator of the strength of
our relationship with Bayer Animal Health in Australia,” said Andrew
Grant
, Divisional President of Bioniche Animal Health Export Sales,
Europe and A/Asia. “Angus Australia’s commitment to the exclusive use
of the Bioniche reproductive products distributed by Bayer provides
recognition of the quality of these products and their perceived value
in Angus Australia’s artificial insemination programme.”

Pregnecol(TM) is a well-established pregnant mare serum gonadotrophin (PMSG) – or
equine chorionic gonadotrophin (eCG) – choice of veterinarians and
producers in Australia, and Bioniche is the only supplier of
domestically sourced and manufactured product. Cue-Mate(TM)offers an efficient and flexible progesterone treatment system, using
specially designed treatment pods that attach to a reusable “wishbone”
carrier system to deliver the progesterone for maximum effect. Cue-Mate(TM) is the estrus synchronization device of choice for a growing number of
Australian farmers.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs 214 skilled personnel and has three operating divisions: Human
Health, Animal Health, and Food Safety. The Company’s primary goal is
to develop proprietary cancer therapies supported by revenues from
marketed products in human and animal health. For more information,
please visit www.Bioniche.com.

About Bioniche Animal Health

Bioniche Animal Health develops, manufactures and markets animal health
biopharmaceutical products worldwide. It has product development,
manufacturing and marketing facilities in Belleville, Ontario, Canada;
marketing and production facilities in Athens, Georgia, U.S.A.;
Pullman, Washington, U.S.A.; and Armidale, New South Wales, Australia.
The Company has progressively grown by using biotechnology to provide
the animal health market with innovative solutions to meet the changing
needs of the animal health industry.

The Company has a product portfolio of more than sixty products, which
can be categorized primarily in the following groups: Reproduction and
embryo transfer products; products based on hyaluronans;
immunostimulant products; polyclonal antibodies; vaccine products; and
nutraceuticals. These products are marketed directly to veterinarians in Canada, the United States,
Australia and Europe, and through selected distributors in the rest of
the world.

Bioniche Animal Health (A/Asia) Pty. Ltd. was established as Vetrepharm
(A/Asia) Pty. Ltd. in July, 1988. In 2002, the unit’s name was changed
to Bioniche Animal Health (A/Asia) Pty. Ltd. The business unit has a
broad base, which includes sales and marketing, research and
development, active pharmaceutical ingredient (API) production and
finished sterile injectables facilities. The Australian business is
conducted from two sites: Melbourne, Victoria, where sales and
marketing, customer support and technical service are located; and
Armidale, New South Wales, where production (manufacturing facility,
farm/research and development facility) is located.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.

SOURCE Bioniche Life Sciences Inc.


Source: newswire



comments powered by Disqus